CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

12-827/S009, S010, S011

Trade Name: Robinul & Robinul Forte Tablets

Generic Name: (glycopyrrolate)

Sponsor: A.H. Robins Company

Approval Date: February 18, 1976
# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:**

12-827/S009, S010, S011

## CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this NDA Review.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Approvable Letter</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>Summary Review</td>
</tr>
<tr>
<td>Officer/Employee List</td>
</tr>
<tr>
<td>Office Director Memo</td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>Environmental Assessment</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 12-827/S009, S010, S011

APPROVAL LETTER
A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

Gentlemen:

Reference is made to your supplemental new drug applications dated November 14, 1975, (S-009) January 5, 1976, (S-010) and January 6, 1976, (S-011) submitted pursuant to section 505(b) of the Federal Food, Drug, and Cosmetic Act for Robinul and Robinul Forte (glycopyrrolate) Tablets.

The supplemental applications provide for revisions in the specifications applied to the raw materials to conform to the USP XIX and NF XIV (S-009) and the use of a five year expiration date on Robinul Tablets (S-010) and Robinul Forte Tablets (S-011) packaged in amber glass bottles with metal or screw caps.

We have completed the review of these supplemental new drug applications, and they are approved. Our letter dated December 17, 1975, detailed the conditions relating to the approval of this application.

In the future, it is recommended that the assay results be reported in percent of label claim in addition to percent of initial assay.

Sincerely yours,

E. DeVaughn Belton, M.D.
Director
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO

HFD-110
HFD-110/SCSO
HFD-616
HFL-10
HFD-110/RJWolters/JFLangston/1/27/76/skc/2/2/76
R/D init by: RJWolters 1/27/76, JLangston 1/28/76, EDBelton 1/29/76

APPROVAL

RJWolters 2/11/76
JLangston 2/1/76
APPLICATION NUMBER:
NDA 12-827/S009, S010, S011

CHEMISTRY REVIEW(S)
**CHEMIST'S REVIEW**

<table>
<thead>
<tr>
<th>1. ORGANIZATION</th>
<th>2. NDA NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFD-110</td>
<td>12-827</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. NAME AND ADDRESS OF APPLICANT (City and State)</th>
<th>DATE NDA APPROVED:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. H. Robins Company</td>
<td>8-11-61</td>
</tr>
<tr>
<td>Richmond, Virginia 23220</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. AF NUMBER</th>
<th>5. SUPPLEMENT (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16-375</td>
<td>NUMBER(S) DATE(S)</td>
</tr>
<tr>
<td></td>
<td>S-009 11-14-75</td>
</tr>
<tr>
<td></td>
<td>S-010 1-5-76</td>
</tr>
<tr>
<td></td>
<td>S-011 1-6-76</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. NAME OF DRUG</th>
<th>7. NONPROPRIETARY NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robinul and Robinul Forte</td>
<td>Glycopyrrolate</td>
</tr>
</tbody>
</table>

| 8. SUPPLEMENT(S) PROVIDES FOR: |
| S-009 provides for revisions in the specifications applied to the raw materials to conform to the USP XIX and NF XIV. |

| 9. AMENDMENTS AND OTHER (Reports, etc.) DATES |
| S-010 and S-011 provide for a 5 year expiration date for Robinul and Robinul Forte. |

| 10. PHARMACOLOGICAL CATEGORY |
| Anticholinergic |

<table>
<thead>
<tr>
<th>11. HOW DISPENSED</th>
</tr>
</thead>
<tbody>
<tr>
<td>(X) RX  OTC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. RELATED IND/NDA/DMP(S)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>13. DOSAGE FORM(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. POTENCY (ies)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg and 2 mg (Forte)</td>
</tr>
</tbody>
</table>

| 15. CHEMICAL NAME AND STRUCTURE |
| See NF XIV |

| 16. RECORDS AND REPORTS |
| CURRENT |
| REVIEWED |
| YES | NO |

| 17. COMMENTS |
| Supplement S-009 was submitted to revised the specifications and tests applied to the raw materials to conform to the revisions in the USP XIX and NF XIV. All of the compendium specifications and tests are performed on the raw materials with the exception of . The NDA has a pH specification of __________ while the USP XIX specification is 4.5 to 7.0. This difference in the pH specification will not appreciably change the quality or purity of . S-010 contained stability data on / lots of the tablets packaged in amber glass bottles with metal screw caps. The conditions were / months at ℃; / year at ℃; and / years at RT. The assay and disintegration results are satisfactory. Recommend to firm that in the future they report the assay results in percent of label claim in addition to percent of initial assay. |

| 18. CONCLUSIONS AND RECOMMENDATIONS |
| Approve the supplements. |

**REVIEWER**

<table>
<thead>
<tr>
<th>NAME</th>
<th>SIGNATURE</th>
<th>DATE COMPLETED</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. J. Wolters</td>
<td>Wolters</td>
<td>2-71-76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1-27-76</td>
</tr>
</tbody>
</table>

**DISTRIBUTION**

<table>
<thead>
<tr>
<th>FORM FDH 2266 (7/75)</th>
<th>ORIGINAL JACKET</th>
<th>REVIEWER</th>
<th>DIVISION FILE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORIG NDA, HFD-110, HFD-110/SCSO, HFD-110/RJWolters/dsc/1.27.76</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 12-827/S009, S010, S011

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
A. H. Robins Company  
Attention: A. M. Stranz  
1407 Cummings Drive  
Richmond, Virginia 23220

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul Forte Tablets  
NDA Number: 12-827  
Supplement Number: S-011  
Date of Supplement: January 6, 1976  
Date of Receipt: January 9, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs  
HFD-110  
Attention: DOCUMENT CONTROL ROOM #16B-30  
5600 Fishers Lane  
Rockville, Maryland 20852

Sincerely yours,

[Signature]

Thomas H. Davis  
Supervisory Consumer Safety Officer  
Division of Cardio-Renal  
Drug Products  
Bureau of Drugs

cc: BLT-DO  
NDA Orig.  
HFD-110  
HFD-110/SCSO  
HFD-110/ALBrown/cg/1/23/76

SUPPLEMENT ACKNOWLEDGEMENT
NDA 12-827

A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia 23220

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul and Robinul Forte
NDA Number: 12-827
Supplement Number: S-009
Date of Supplement: November 14, 1975
Date of Receipt: January 5, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs HFD-110
Attention: DOCUMENT CONTROL ROOM #16B-30
5600 Fishers Lane
Rockville, Maryland 20852

Sincerely yours,

Thomas H. Davis
Supervisory Consumer Safety Officer
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc: BLT-DO
NDA Orig.
HFD-110
HFD-110/SCSO
HFD-110/ALBrown/1/19/76/ep/1/20/76
A. H. Robins Company
Attention: A. M. Stranz
1407 Cummings Drive
Richmond, Virginia  23220

Gentlemen:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Robinul Tablets
NDA Number: 12-827
Supplement Number: S-010
Date of Supplement: January 5, 1976
Date of Receipt: January 8, 1976

All communications concerning this NDA should be addressed as follows:

Bureau of Drugs  HFD-110
Attention: DOCUMENT CONTROL ROOM #16B-30
5600 Fishers Lane
Rockville, Maryland  20852

Sincerely yours,

Thomas H. Davis
Supervisory Consumer Safety Officer
Division of Cardio-Renal
Drug Products
Bureau of Drugs

cc:  BLT-DO
NDA Orig.
HFD-110
HFD-110/SCSO
HFD-110/ALBrown/cg/1/23/76

SUPPLEMENT ACKNOWLEDGEMENT
January 6, 1976

Re: NDA 12-827

Robinul Forte Tablets

Gentlemen:

This manufacturing supplement to our New Drug Application for Robinul Forte Tablets is submitted under the provisions of paragraph 314.8(a)(5)(ix) which permits the initiation of expiration dating prior to approval of an NDA supplement.

An expiration date of five years will be revealed on the immediate container labels of all Robinul Forte Tablets packaged after January 1, 1976. This revision in label information is made to comply with the National Formulary XIV which became official in July 1975.

Enclosed in triplicate are copies of the 5-year stability summary for this product and copies of : used to obtain the results.

Enclosed also are twelve (12) example labels which illustrate this new development. Any future change in the dating period established by this submission will be proposed in a supplemental application and will not be put into effect until the supplement is approved.

All other sections of the NDA remain unchanged.

Sincerely,

[Signature]

A. M. Stranz
Manager, Drug Registration

A. H. Robins Company
1407 Cummings Drive
Richmond, Virginia 23220
Telephone (804) 257-2546

Bureau of Drugs HFD-110
Room 16-B-30
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20852

Enclosures: 5-year stability summary for Lots 63, 64, 65

Labels
8 Page(s) Withheld

/ Trade Secret / Confidential (b4)

/ Draft Labeling (b4)

/ Draft Labeling (b5)

/ Deliberative Process (b5)

Withheld Track Number: Administrative- 12-872
S009, S010, S011
Gentlemen:

This manufacturing supplement to our New Drug Application for Robinul Tablets is submitted under the provisions of paragraph 314.8(a) (5) (ix) which permits the initiation of expiration dating prior to approval of an NDA supplement.

An expiration date of five years will be revealed on the immediate container labels of all Robinul Tablets packaged after January 1, 1976. This revision in label information is made to comply with the National Formulary XIV which became official in July 1975.

Enclosed in triplicate are copies of the 5-year stability summary for this product and copies of used to obtain the results.

Enclosed also are twelve (12) example labels which illustrate this new development. Any future change in the dating period established by this submission will be proposed in a supplemental application and will not be put into effect until the supplement is approved.

All other sections of the NDA remain unchanged.

Sincerely,

A. M. Stranz

Enclosures: 5-year stability summary for Lots 231, 232, 233
Labels
7 Page(s) Withheld

\[ \text{\underline{\hspace{4cm}}} \text{ Trade Secret / Confidential (b4)} \]

\[ \text{\underline{\hspace{4cm}}} \text{ Draft Labeling (b4)} \]

\[ \text{\underline{\hspace{4cm}}} \text{ Draft Labeling (b5)} \]

\[ \text{\underline{\hspace{4cm}}} \text{ Deliberative Process (b5)} \]

Withheld Track Number: Administrative-\text{\underline{\hspace{1cm}}}
SUBJECT: Changes in Publications and Official Pharmacopoeial Standard Substances
Reference USP XIX and/or NF XIV 1975
NDA #12-827
Robinul and Robinul Forte
Citation 21CFR §314.8

Gentlemen:

This is a supplement to our New Drug Application for Robinul and Robinul Forte Tablets NDA #12-827.

It is submitted under the provisions of 21CFR §314.8 for the purposes cited above.

Upon the appearance of the new editions of the recognized U.S. pharmacopoeias, a corresponding change is made in our raw material and test procedures found in our respective new drug applications. Since the USP and NF were automatically accorded recognition in July 1975, A. H. Robins has ensured that our drug products meet any new requirements found in the respective official monographs and/or standards.
Enclosed are the following raw material pharmacopoeial specifications applied to the above-cited New Drug Application and referenced in the 1975 USP and/or NF.

<table>
<thead>
<tr>
<th>Robinul</th>
<th>Robinul Forte</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Glycopyrrolate</td>
<td>1. Glycopyrrolate</td>
</tr>
<tr>
<td>2.</td>
<td>b(4)</td>
</tr>
<tr>
<td>3.</td>
<td>b(4)</td>
</tr>
<tr>
<td>4.</td>
<td>b(4)</td>
</tr>
<tr>
<td>5.</td>
<td>b(4)</td>
</tr>
</tbody>
</table>

Sincerely,

A. M. Stranz
Page(s) Withheld

☐ Trade Secret / Confidential (b4)

☐ Draft Labeling (b4)

☐ Draft Labeling (b5)

☐ Deliberative Process (b5)

Withheld Track Number: Administrative-28-827
5004, 5010
5011
NOTICE OF APPROVAL
NEW DRUG APPLICATION OR SUPPLEMENT

TO: Press Relations Staff (PA-40)
FROM: Bureau of Drugs

ATTENTION
Forward original of this form for publication only after approval letter has been issued and the date of approval has been entered above.

TYPE OF APPLICATION
☑ ORIGINAL NDA ☐ SUPPLEMENT ☑ ABREVIATED NDA ☐ SUPPLEMENT TO ANDA CATEGORY
X HUMAN ☐ VETERINARY

TRADE NAME (or other designated name) AND ESTABLISHED OR NONPROPRIETARY NAME (if any) OF DRUG
Robinul and Robinul Forte (glycopyrrolate)

DOSAGE FORM
TABLET
HOW DISPENSED
☑ RX ☐ OTC

ACTIVE INGREDIENT(S) (as declared on label. List by established or nonproprietary name(s) and include amount(s), if amount is declared on label.)
Glycopyrrolate 1 mg and Forte 2 mg

NAME OF APPLICANT (Include City and State)
A. H. Robins Company
Richmond, Virginia 23220

PRINCIPAL INDICATION OR PHARMACOLOGICAL CATEGORY
Anticholinergic

ANIMAL SPECIES FOR WHICH APPROVED

CHANGE APPROVED TO PROVIDE FOR S-009 Controls revisions.
S-010 and S-011 Expiration dates

FORM PREPARED BY
NAME: R. J. Wolters
DATE: 2-11-76

FORM APPROVED BY
NAME: J. F. Langston
DATE: 2-11-76